Spironolactone or Finerenone

PreclinicalSmall molecule

Spironolactone or Finerenone is one of 7 small molecule programs targeting Alport syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alport SyndromeActive, not recruiting

Alport SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Alport Syndrome

#DrugCompanyPhaseTrials

Lescol

Glucophage

1 3

BAY 987519

Bayer

Phase 2

1 4

Farxiga

AstraZeneca

Preclinical

1 5

Zemplar

AbbVie

Preclinical

1 6

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 7

Spironolactone or Finerenone

UUniversity Hospital Goettingen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2036

Recruiting

Alport Syndrome

NCT02378805

Clinical

Trials by Indication[1]

Alport syndrome1 trial

Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

Recruiting·UUniversity Hospital Goettingen··NCT02378805·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Spironolactone or Finerenone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spironolactone or Finerenone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spironolactone or Finerenone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Goettingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital Goettingen

Spironolactone or Finerenone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2036

Trials by Indication[1]

Alport syndrome1 trial

References

Drug Info

Quick Facts

Related News